Slides on Key Decisions in HIV Care: Optimizing Switch Strategies for Patients With Viral Suppression

Learn key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens.
Daniel R. Kuritzkes, MD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 908 KB
Released: June 7, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Milosz Parczewski and Clinical Care Options (CCO): Update from EACS 2021 on the HIV care continuum in Eastern Europe

Milosz Parczewski, MD, PhD Released: December 3, 2021

Slides from Dr Milena Murray and Clinical Care Options (CCO): Data suggests patient factors that may inform candidacy for LA CAB + RPV as a treatment option

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: December 1, 2021

Commentary from Dr Yan Zhao on the latest findings from EACS 2021 highlighting the unique challenges of older people living with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 30, 2021

Expert commentary on what long-acting ART means for people with HIV, from Dr Jean-Michel Molina and Clinical Care Options (CCO)

Jean-Michel Molina, MD, PhD Released: November 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue